CTLA4 and non-small cell lung carcinoma: Consistently, Anagnostou V. et al. found that non-small cells carcinoma (NSCC) relapsed following treatment with anti-PD1 and CTLA-4 checkpoint blockade bear similar neoantigen load, with only a relatively small number of putative deleted clones (Anagnostou et al., 2017).